Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen    QGEN   NL0012169213

QIAGEN

(QGEN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 04:10pm EDT

DGAP Voting Rights Announcement: QIAGEN N.V.
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

25.06.2019 / 22:08
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


The AFM (the Netherlands Authority For the Financial Markets has informed us on June 21, 2019 that a notification related to our institution has been released by the AFM.

The following notification has been disclosed in the relevant register on the AFM website:

Date of transaction: 19 june 2019
Person obliged to notify: BlackRock, Inc.
Issuing institution: Qiagen N.V.
Registration Chamber of Commerce: 12036979
Place of residence: VENLO

Distribution in numbers

Type of share Number of shares Number of voting rights Capital interest Voting rights Manner of disposal Settlement
Ordinary share 21.626.869,00 24.271.503,00 Real Real Indirectly - BlackRock, Inc  
Ordinary share 1.126.786,00 1.189.932,00 Potential Potential Indirectly - BlackRock, Inc. Physical Delivery
Contract for difference 39.364,00 39.364,00 Potential Potential Indirectly - BlackRock, Inc. In cash
 


Distribution in percentages

Type Total holding Directly real Directly potential Indirectly real Indirectly potential
Capital interest 9,87 % 0,00 % 0,00 % 9,37 % 0,51 %
Voting rights 11,05 % 0,00 % 0,00 % 10,51 % 0,53 %
 

QIAGEN N.V. is not responsible for the accuracy and correctness of the notification above. The content has been taken from the relevant register of the AFM: https://www.afm.nl/en/professionals/registers/meldingenregisters/substantiele-deelnemingen/details?id=75401



25.06.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Internet: www.qiagen.com

 
End of News DGAP News Service

828643  25.06.2019 

fncls.ssp?fn=show_t_gif&application_id=828643&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on QIAGEN
07/16QIAGEN N.V. : to Report Second Quarter and First Half of 2019 Results
BU
07/15QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
07/09QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/25QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
06/25QIAGEN : Clinical Insight surpasses 1 million patient test cases analyzed and in..
AQ
06/24QIAGEN N.V. : Release of a capital market information
EQ
06/21QIAGEN : New NGS panel for rare and inherited diseases with advanced bioinformat..
AQ
06/21QIAGEN : QCI-Lab performing expanded carrier screening boosts efficiency by 80%
AQ
06/20QIAGEN : Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed and In..
BU
More news
Financials (USD)
Sales 2019 1 578 M
EBIT 2019 430 M
Net income 2019 210 M
Debt 2019 771 M
Yield 2019 -
P/E ratio 2019 44,7x
P/E ratio 2020 35,0x
EV / Sales2019 6,15x
EV / Sales2020 5,54x
Capitalization 8 943 M
Chart QIAGEN
Duration : Period :
Qiagen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 42,23  $
Last Close Price 39,54  $
Spread / Highest target 26,5%
Spread / Average Target 6,81%
Spread / Lowest Target -8,95%
EPS Revisions
Managers
NameTitle
Peer Michael Schatz Chief Executive Officer & Managing Director
Sven Håkan Björklund Chairman-Supervisory Board
Douglas Liu Senior Vice President-Global Operations
Manuel O. Mendez Senior Vice President-Global Commercial Operations
Roland Sackers Chief Financial Officer & Managing Director
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN15.70%8 943
IQVIA HOLDINGS INC34.16%30 740
LONZA GROUP31.57%25 623
CELLTRION, INC.--.--%20 071
INCYTE CORPORATION26.66%17 271
EXACT SCIENCES CORPORATION85.26%14 835